Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 15Neoplasms 3Colorectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Disease Progression 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

durvalumab 2Nivolumab 2Gemcitabine 2tremelimumab 1regorafenib 1nilotinib 1neratinib 1encorafenib 1Valproic Acid 1Taxes 1Standard of Care 1Radiomics 1Practice Guidelines as Topic 1Palliative Care 1Oxaliplatin 1Leucovorin 1Hepatectomy 1Folfox protocol 1Fluorouracil 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Clinical Trials as Topic 1Cisplatin 1Cetuximab 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × nilotinib × Gastrointestinal × Clear all
NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
2 enrolled
GastrointestinalSarcoma

Disease Progression, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡